Frontline of ASCT in High-risk DLBCL

This study is testing whether adding a stem cell transplant (using the patient's own stem cells) to standard chemotherapy works better as a first-line treatment for people with high-risk diffuse large B-cell lymphoma (DLBCL), a fast-growing type of blood cancer. Participants must not have received any prior treatment for this cancer. **You may be eligible if...** - You have been newly diagnosed with high-risk DLBCL (a type of aggressive blood cancer) - Your cancer is measurable and has a high-risk score (IPI score of 3 or more) - You have not yet started treatment - Your heart, kidney, and liver function are adequate **You may NOT be eligible if...** - You have previously received certain chemotherapy drugs (anthracyclines) or have a reason you cannot receive standard chemo - Your lymphoma has spread to the brain or spinal cord - You have another active cancer Talk to your doctor to see if this trial is right for you.